Search

Your search keyword '"Choo, Su Pin"' showing total 27 results

Search Constraints

Start Over You searched for: Author "Choo, Su Pin" Remove constraint Author: "Choo, Su Pin" Database OpenAIRE Remove constraint Database: OpenAIRE
27 results on '"Choo, Su Pin"'

Search Results

1. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

2. Combined burden and functional impact tests for cancer driver discovery using DriverPower

3. Integrative pathway enrichment analysis of multivariate omics data

4. Pathway and network analysis of more than 2500 whole cancer genomes

5. Divergent mutational processes distinguish hypoxic and normoxic tumours

6. Genomic footprints of activated telomere maintenance mechanisms in cancer

7. Additional file 1 of A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

8. Additional file 2 of A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

9. Nivolumab for the treatment of hepatocellular carcinoma

10. INC280X2201_HCC_Manuscript_Supplementary_Figure_S1 – Supplemental material for A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

11. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

12. INC280X2201_HCC_Manuscript_Supplementary_Table_S2 – Supplemental material for A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

13. INC280X2201_HCC_Manuscript_Supplementary_Table_S3 – Supplemental material for A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

14. INC280X2201_HCC_Manuscript_Supplementary_Table_S1 – Supplemental material for A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

15. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with -Mutated Hepatocellular Carcinoma

16. Targeted Therapy in Hepatocellular Carcinoma

17. Sex differences in oncogenic mutational processes

18. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

20. Sex differences in oncogenic mutational processes

21. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

24. Pan-cancer analysis of whole genomes

25. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

26. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

27. Nivolumab (NIVO) plus ipilimumab (IPI) plus cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040

Catalog

Books, media, physical & digital resources